OR WAIT 15 SECS
UK cell and gene therapy location expected to be cGMP-ready by mid-2022
Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced that it is establishing a Center of Excellence for cell and gene therapy, which will be located in Stevenage, UK. With the newly formed UK subsidiary, Rentschler ATMP Ltd., the CDMO will establish development and manufacturing capability in advanced therapy medicinal products (ATMPs).
The company’s new site is being set up at an existing facility currently run by the Cell and Gene Therapy Catapult (CGT Catapult) through a collaborative model. It expects to be ready for cGMP (current good manufacturing practice) manufacturing by the first half of 2022, and over the next five years, Rentschler Biopharma plans to make a sizeable investment at the site to help provide manufacturing of viral vectors for clinical supply.
At the Center of Excellence, Rentschler Biopharma plans to partner with entrepreneurs with the aim to transform their ideas into real products, while also having the opportunity to treat and possibly cure patients with serious diseases.